Gateway Biotechnology
Gateway Biotechnology is dedicated to developing first-in-class drug therapies for tinnitus and hearing disorders. Founded in 2011 by Drs. Jianxin Bao, Rick Chole, and Philip Perez, the company aims to translate basic scientific discoveries into novel therapies. With a focus on addressing the unmet needs of tinnitus patients, Gateway Biotechnology is advancing innovative solutions like GW-TT2 and GW-TT5 to provide effective treatments for this debilitating condition.
Gateway Biotechnology
701 West Main Street, Suite 200, Durham, NC 27701
What We Do
GW-TT2 is a nasal formulation designed to treat recent onset tinnitus, including tinnitus associated with Ménière’s Disease. It has shown high effectiveness in a mouse model of noise-induced tinnitus.
GW-TT5 is a gene therapy designed to treat severe debilitating tinnitus. It is currently in pre-clinical development.
Application Area
Key People
Co-Founder & CEO
Co-Founder & COO
VP, Clinical Development
News & Updates
Developing Disease-Specific Biomarkers to Sub-Type Acquired Hearing Disorders for Improved Therapeutic Interventions.
Exploring Novel Small Molecule & Gene Therapeutic Approaches for Tinnitus Indications for Improved Patient Care.